1. Potent Inhibition of HIV-1 Replication by a Tat Mutant
- Author
-
Haran Sivakumaran, Andreas Suhrbier, David Harrich, Lee Major, and Luke W. Meredith
- Subjects
Transcription, Genetic ,Mutant ,Green Fluorescent Proteins ,lcsh:Medicine ,Biology ,medicine.disease_cause ,Virus Replication ,03 medical and health sciences ,Transactivation ,medicine ,MRNA transport ,Humans ,RNA, Messenger ,lcsh:Science ,Fluorescent Antibody Technique, Indirect ,030304 developmental biology ,Genes, Dominant ,Virology/Antivirals, including Modes of Action and Resistance ,0303 health sciences ,Mutation ,Multidisciplinary ,030302 biochemistry & molecular biology ,lcsh:R ,Wild type ,Virion ,Transfection ,Exons ,Molecular biology ,Reverse transcriptase ,3. Good health ,Protein Structure, Tertiary ,Viral replication ,Virology/Viral Replication and Gene Regulation ,Virology/Immunodeficiency Viruses ,Gene Products, tat ,HIV-1 ,RNA, Viral ,lcsh:Q ,Research Article ,HeLa Cells - Abstract
Herein we describe a mutant of the two-exon HIV-1 Tat protein, termed Nullbasic, that potently inhibits multiple steps of the HIV-1 replication cycle. Nullbasic was created by replacing the entire arginine-rich basic domain of wild type Tat with glycine/alanine residues. Like similarly mutated one-exon Tat mutants, Nullbasic exhibited transdominant negative effects on Tat-dependent transactivation. However, unlike previously reported mutants, we discovered that Nullbasic also strongly suppressed the expression of unspliced and singly-spliced viral mRNA, an activity likely caused by redistribution and thus functional inhibition of HIV-1 Rev. Furthermore, HIV-1 virion particles produced by cells expressing Nullbasic had severely reduced infectivity, a defect attributable to a reduced ability of the virions to undergo reverse transcription. Combination of these inhibitory effects on transactivation, Rev-dependent mRNA transport and reverse transcription meant that permissive cells constitutively expressing Nullbasic were highly resistant to a spreading infection by HIV-1. Nullbasic and its activities thus provide potential insights into the development of potent antiviral therapeutics that target multiple stages of HIV-1 infection.
- Published
- 2009